Does hyperglycemia affect the diagnostic value of 18F-FDG PET/CT?

Area of Science:

• Nuclear Medicine
• Oncologic Imaging
• Diagnostic Accuracy

Background:

• Elevated plasma glucose levels can negatively impact 18F-FDG uptake.
• Hyperglycemia is a common concern in patients undergoing PET/CT scans.

Purpose of the Study:

• To evaluate the effect of hyperglycemia on the diagnostic accuracy of 18F-FDG PET/CT in oncologic patients.
• To determine if elevated glucose levels compromise the reliability of PET/CT imaging.

Main Methods:

• Retrospective review of 76 oncologic patients with pre-scan glucose > 140 mg/dL.
• Assessment of PET/CT accuracy against CT, MRI, histology, and clinical follow-up.
• Analysis of diagnostic performance metrics including sensitivity, specificity, and overall accuracy.

Main Results:

• Overall diagnostic accuracy was 88.1% (sensitivity 86%, specificity 90.9%).
• PET/CT demonstrated high accuracy in identifying malignant lesions despite hyperglycemic states.
• No significant difference in diagnostic accuracy was observed between diabetic and non-diabetic patients.

Conclusions:

• 18F-FDG PET/CT maintains reliable diagnostic accuracy in hyperglycemic states for oncologic indications.
• Malignant lesion uptake is generally sufficient for qualitative diagnosis.
• Further research is needed to fully elucidate the impact of hyperglycemia on PET/CT accuracy.